HIF1A and hepatocellular carcinoma: HIF-1α inhibition could be relevant to the resolution of all NAFLD-related clinical parameters (including steatosis, chronic hepatitis, and fibrosis) and HCC, whereas its activation is relevant to the protection against ischemia/reperfusion- (I/R-) related injury and acute hepatitis [59].